array(3) {
["company_details"]=>
array(13) {
["name"]=>
string(26) "Bio-RAD Laboratories, Inc."
["slug"]=>
string(33) "001cd-us-bio-rad-laboratories-inc"
["logo"]=>
string(84) "https://images.businessradar.com/linkedin_logos/9d1c28c2-1b47-4093-8ed2-5151f3fe7920"
["description"]=>
string(867) "Since Bio-Rad was founded 70 years ago, we have continued to provide the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and medical diagnostic labs obtain faster, better results. Throughout our existence, we have built long-lasting customer relationships that help advance our research and development efforts in the introduction of new products and solutions. Today, Bio-Rad is a global leader, with a team of over 8,000 employees and a global network of operations that serves our life science research and clinical diagnostics customers, advancing science and saving lives, together.
#Biotechnology #Biotech #STEM #Research #Biology #Chemistry #Science #PeerReviewed #Diabetes #CancerResearch #HIVResearch #Laboratory #BioRad #Cancer #DiabetesResearch #AIDSResearch #ClinicalDiagnostics"
["address_street"]=>
string(20) "1000 Alfred Nobel Dr"
["address_place"]=>
string(8) "Hercules"
["address_region"]=>
string(10) "California"
["founding_date"]=>
string(10) "1952-02-08"
["website_domain"]=>
string(11) "bio-rad.com"
["website_url"]=>
string(23) "https://www.bio-rad.com"
["industry_codes"]=>
array(3) {
[0]=>
string(42) "In Vitro and In Vivo Diagnostic Substances"
[1]=>
string(33) "Laboratory Analytical Instruments"
[2]=>
string(47) "Electromedical and Electrotherapeutic Apparatus"
}
["employee_count"]=>
int(7900)
["article_count"]=>
int(683)
}
["articles"]=>
array(5) {
[0]=>
array(7) {
["title_en"]=>
string(97) "Qiagen Cites Competitive Advantages in Digital PCR, Sequencing Assays as Part of Core Growth Plan"
["snippet_en"]=>
string(137) "On a call with investors to discuss third quarter results, the firm also offered updates on its syndromic testing and NeuMoDx businesses."
["url"]=>
string(122) "https://www.genomeweb.com/business-news/qiagen-cites-competitive-advantages-digital-pcr-sequencing-assays-part-core-growth"
["image_url"]=>
NULL
["source"]=>
string(13) "genomeweb.com"
["publication_date"]=>
string(10) "2022-11-08"
["categories"]=>
array(5) {
[0]=>
string(13) "Data Security"
[1]=>
string(24) "Quarterly/Annual Figures"
[2]=>
string(41) "E-commerce and Technological Developments"
[3]=>
string(14) "Product Launch"
[4]=>
string(25) "Business Model Resilience"
}
}
[1]=>
array(7) {
["title_en"]=>
string(48) "Bio-Rad and Qiagen in Merger Talks? | CHEManager"
["snippet_en"]=>
string(244) "News
Bio-Rad and Qiagen in Merger Talks? 12.10.2022- Bio-Rad Laboratories is in talks to merge with fellow life-sciences company Qiagen in a deal that could be worth more than$ 10 billion, US business newspaper Wall Street Journal has reported,"
["url"]=>
string(73) "https://www.chemanager-online.com/en/news/bio-rad-and-qiagen-merger-talks"
["image_url"]=>
NULL
["source"]=>
string(21) "chemanager-online.com"
["publication_date"]=>
string(10) "2022-10-12"
["categories"]=>
array(3) {
[0]=>
string(6) "Merger"
[1]=>
string(25) "Business Model Resilience"
[2]=>
string(21) "Competitive Behaviour"
}
}
[2]=>
array(7) {
["title_en"]=>
string(146) "Global Antimicrobial Susceptibility Testing Market 2019-2023| Evolving Opportunities with bioMérieux SA and Bio-Rad Laboratories Inc. | Technavio"
["snippet_en"]=>
string(133) "The global antimicrobial susceptibility testing market is poised to grow by USD 832.14 million during 2019-2023 at a CAGR of over 5%."
["url"]=>
string(204) "https://www.businesswire.com/news/home/20191121005577/en/Global-Antimicrobial-Susceptibility-Testing-Market-2019-2023-Evolving-Opportunities-with-bioM%C3%A9rieux-SA-and-Bio-Rad-Laboratories-Inc.-Technavio"
["image_url"]=>
NULL
["source"]=>
string(16) "businesswire.com"
["publication_date"]=>
string(10) "2019-11-21"
["categories"]=>
array(2) {
[0]=>
string(15) "Market Movement"
[1]=>
string(25) "Business Model Resilience"
}
}
[3]=>
array(7) {
["title_en"]=>
string(36) "BUSINESS DIGEST -- Regional Earnings"
["snippet_en"]=>
string(36) "Bio-Rad Laboratories Inc. (Hercules)"
["url"]=>
string(85) "https://www.sfgate.com/business/article/BUSINESS-DIGEST-Regional-Earnings-3021623.php"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/8e47cba1-88f3-4dc6-b657-37f0980e019e"
["source"]=>
string(10) "sfgate.com"
["publication_date"]=>
NULL
["categories"]=>
array(3) {
[0]=>
string(25) "Business Model Resilience"
[1]=>
string(20) "Business Development"
[2]=>
string(24) "Quarterly/Annual Figures"
}
}
[4]=>
array(7) {
["title_en"]=>
string(50) "Qiagen: Good business even without the Corona hype"
["snippet_en"]=>
string(239) "02/06/2023 - Acquisitions are part of Qiagen's business model. The specialist in diagnostics has just announced the takeover of its American cooperation partner Verogen for 150 million dollars. The acquisition has specialized in forensics."
["url"]=>
string(94) "https://www.wallstreet-online.de/nachricht/16522246-egbert-prior-qiagen-geschaefte-corona-hype"
["image_url"]=>
string(78) "https://images.businessradar.com/articles/c65fbbf0-ce0b-4428-b5ae-7eaf352ca9bc"
["source"]=>
string(20) "wallstreet-online.de"
["publication_date"]=>
NULL
["categories"]=>
array(5) {
[0]=>
string(6) "Merger"
[1]=>
string(25) "Business Model Resilience"
[2]=>
string(8) "Epidemic"
[3]=>
string(27) "Business Model & Innovation"
[4]=>
string(11) "Acquisition"
}
}
}
["category_annotations"]=>
array(30) {
[0]=>
array(2) {
["name"]=>
string(12) "Stock Market"
["count"]=>
int(66)
}
[1]=>
array(2) {
["name"]=>
string(24) "Quarterly/Annual Figures"
["count"]=>
int(51)
}
[2]=>
array(2) {
["name"]=>
string(14) "Product Launch"
["count"]=>
int(32)
}
[3]=>
array(2) {
["name"]=>
string(15) "Market Movement"
["count"]=>
int(30)
}
[4]=>
array(2) {
["name"]=>
string(5) "Legal"
["count"]=>
int(26)
}
[5]=>
array(2) {
["name"]=>
string(17) "Academic Research"
["count"]=>
int(24)
}
[6]=>
array(2) {
["name"]=>
string(31) "Financial Update/Profit Warning"
["count"]=>
int(23)
}
[7]=>
array(2) {
["name"]=>
string(18) "General Investment"
["count"]=>
int(20)
}
[8]=>
array(2) {
["name"]=>
string(8) "Epidemic"
["count"]=>
int(19)
}
[9]=>
array(2) {
["name"]=>
string(5) "R & D"
["count"]=>
int(19)
}
[10]=>
array(2) {
["name"]=>
string(11) "Acquisition"
["count"]=>
int(19)
}
[11]=>
array(2) {
["name"]=>
string(24) "Stock Research & Ratings"
["count"]=>
int(18)
}
[12]=>
array(2) {
["name"]=>
string(18) "Ecological Impacts"
["count"]=>
int(15)
}
[13]=>
array(2) {
["name"]=>
string(14) "Issuing Shares"
["count"]=>
int(14)
}
[14]=>
array(2) {
["name"]=>
string(10) "Litigation"
["count"]=>
int(14)
}
[15]=>
array(2) {
["name"]=>
string(13) "Collaboration"
["count"]=>
int(13)
}
[16]=>
array(2) {
["name"]=>
string(18) "Expansion & Growth"
["count"]=>
int(10)
}
[17]=>
array(2) {
["name"]=>
string(12) "Board Change"
["count"]=>
int(10)
}
[18]=>
array(2) {
["name"]=>
string(10) "New Market"
["count"]=>
int(9)
}
[19]=>
array(2) {
["name"]=>
string(11) "Regulations"
["count"]=>
int(9)
}
[20]=>
array(2) {
["name"]=>
string(21) "Competitive Behaviour"
["count"]=>
int(8)
}
[21]=>
array(2) {
["name"]=>
string(6) "Merger"
["count"]=>
int(7)
}
[22]=>
array(2) {
["name"]=>
string(46) "Management of Legal and Regulatory Environment"
["count"]=>
int(7)
}
[23]=>
array(2) {
["name"]=>
string(27) "Business Model & Innovation"
["count"]=>
int(7)
}
[24]=>
array(2) {
["name"]=>
string(11) "Competition"
["count"]=>
int(7)
}
[25]=>
array(2) {
["name"]=>
string(16) "Case Settlements"
["count"]=>
int(6)
}
[26]=>
array(2) {
["name"]=>
string(13) "Credit Rating"
["count"]=>
int(5)
}
[27]=>
array(2) {
["name"]=>
string(15) "Business Ethics"
["count"]=>
int(5)
}
[28]=>
array(2) {
["name"]=>
string(25) "Business Model Resilience"
["count"]=>
int(5)
}
[29]=>
array(2) {
["name"]=>
string(15) "Deals & Tenders"
["count"]=>
int(5)
}
}
}
001cd-us-bio-rad-laboratories-inc
Bio-RAD Laboratories, Inc.
Location
California
Founded
1952-02-08
Website
https://www.bio-rad.com
Articles
683 Articles
Category
In Vitro and In Vivo Diagnostic Substances
Laboratory Analytical Instruments
Electromedical and Electrotherapeutic Apparatus
Description
Since Bio-Rad was founded 70 years ago, we have continued to provide the healthcare industry with innovative and useful products that help life science researchers accelerate the discovery process and medical diagnostic labs obtain faster, better results. Throughout our existence, we have built long-lasting customer relationships that help advance our research and development efforts in the introduction of new products and solutions. Today, Bio-Rad is a global leader, with a team of over 8,000 employees and a global network of operations that serves our life science research and clinical diagnostics customers, advancing science and saving lives, together.
#Biotechnology #Biotech #STEM #Research #Biology #Chemistry #Science #PeerReviewed #Diabetes #CancerResearch #HIVResearch #Laboratory #BioRad #Cancer #DiabetesResearch #AIDSResearch #ClinicalDiagnostics
News
Bio-Rad and Qiagen in Merger Talks? 12.10.2022- Bio-Rad Laboratories is in talks to merge with fellow life-sciences company Qiagen in a deal that could be worth more than$ 10 billion, US business newspaper Wall Street Journal has reported,
02/06/2023 - Acquisitions are part of Qiagen's business model. The specialist in diagnostics has just announced the takeover of its American cooperation partner Verogen for 150 million dollars. The acquisition has specialized in forensics.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
